Cancer Clinical Trials Results
PREOPERATIVE FOLFIRINOX FOR RESECTABLE PANCREATIC ADENOCARCINOMA – A PHASE II STUDY
||Main Campus|| ||Phase 2||Pancreas
Outcomes Registry of Patients with Pancreatic Cancer Undergoing Definitive Treatment at Cleveland Clinic
||Main Campus|| || ||Pancreas
A Phase 3, multicenter, open-label, randomized study of nab®-paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma
||Fairview, Hillcrest, Independence, Main Campus|| ||Phase 3||Pancreas
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
||Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster|| ||Phase 2||Pancreas
A Phase II-R and A Phase III Trial Evaluating both *Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
||Beachwood, Fairview, Hillcrest, Independence, Mansfield, North Coast Cancer, Strongsville, Wooster||Stage 3||Phase 2, Phase 3||Pancreas
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2015 Cleveland Clinic. All rights reserved.